Skip to content

FDA Modernization Act 3.0

Passed first chamber: it can still change before the session ends.

US HR 2821 · House Bill · 119th Congress

Draft a letter
Stage
Passed first chamber
Started in
House
Sponsors
42
Latest action
Jul 21, 2026

What it does

FDA Modernization Act 3.0 This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug. The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications. The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.

Official summary · Introduced in House · Apr 10, 2025

Titles and provisions can change as the bill moves.

Read the full textRead it on the official site

Where it stands

  1. Introduced (Done)

    Apr 10, 2025

  2. Committee (Done)

  3. Floor (Current step)

    Passed first chamber · Jul 21, 2026

  4. Law (Not started)

What moved

Loading recorded actions…

Who is involved

Sponsors

The lawmakers who put their names on it, lead sponsors first.

Where it goes next

While a bill can still move, the questions are about people and money.

Work with this bill

FDA Modernization Act 3.0 | 52